U.S. drug distributors urge govt to boost COVID-19 vaccine supply network
Reuters
Published Mar 15, 2021 04:55PM ET
Updated Mar 15, 2021 05:05PM ET
(Reuters) - Three major U.S. drug distributors have requested the government to expand the COVID-19 vaccine supply chain network as the country strives to immunize its population against the novel coronavirus as quickly as possible.
AmerisourceBergen (NYSE:ABC) Corp, Cardinal Health Inc (NYSE:CAH) and Henry Schein Inc (NASDAQ:HSIC) in a letter urged officials to develop a plan of action aimed at identifying ways to move the vaccines safely and quickly to administrators and vaccination sites.
The Federal Emergency Management Agency, to whom the letter was addressed, did not immediately respond to a Reuters request for comment.
The companies said on Monday the existing healthcare network, including pharmacies, doctors' offices, hospitals and other healthcare providers, will need to be activated to achieve herd immunity against the virus.
Reuters first reported in January that Cardinal Health and AmerisourceBergen Corp were in talks with federal officials about increasing the number of companies shipping coronavirus vaccines as part of the Biden administration's push to speed up inoculations. (https://reut.rs/3rSvlGu)
The U.S government in February authorized Johnson & Johnson (NYSE:JNJ)'s single-dose COVID-19 vaccine for emergency use, making it the third vaccine to become available in the country, after those developed by Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc received authorization late last year.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.